BNRNasdaqServices-Medical Laboratories

Burning Rock Biotech Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026

$12.29−0.61 (-4.73%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2017 to 2025

74.7%+1.7 pts over 5 years

-10.2%+85.8 pts over 5 years

-10.3%+84.5 pts over 5 years

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	+4.6%	-1.4%	+4.6%	–
Gross profit	+11.2%	+2.0%	+5.1%	–

9 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2017	FY2020	FY2025
Return on equity	–	-53.3%	-9.9%
Return on assets	–	-23.2%	-6.5%
Current ratio	–	10.45	2.99
Debt to equity	–	0.00	0.00
Net debt to EBITDA	–	5.07×	14.41×
Interest coverage	–	-618.3×	–
Inventory turnover	–	1.8×	2.7×
Capex to revenue	–	14.0%	1.0%
Diluted shares	–	0M	–

Return on equity split into margin, efficiency and leverage

Net margin-10.3%

Asset turnover0.63×

Equity multiplier1.53×

Return on equity, FY2025-9.9%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-10.3%	0.63×	1.53×	-9.9%
FY2024	-67.2%	0.54×	1.43×	-51.4%
FY2023	-121.6%	0.41×	1.36×	-67.9%
FY2022	-172.4%	0.29×	1.29×	-64.7%
FY2021	-156.9%	0.21×	1.16×	-37.3%
FY2020	-94.7%	0.24×	2.30×	-53.3%

Parsed from the XBRL in Burning Rock Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on May 15, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BNR.

Revenue growth4.6% · median 42.7%

Gross margin74.7% · median 68.1%

Operating margin-10.2% · median 10.9%

Net margin-10.3% · median 9.5%

Advertisement
300 × 250